Isotretinoin
Isotretinoin is a teratogen; there is about a 20–35% risk for congenital defects in infants exposed to the drug "in utero", and about 30–60% of children exposed to isotretinoin prenatally have been reported to show neurocognitive impairment. Because of this, there are strict controls on prescribing isotretinoin to women who may become pregnant and women who become pregnant while taking isotretinoin are strongly advised to terminate their pregnancies.
Eskatrol
In August 1970 the F.D.A. sought to limit the use of stimulants by calling for changes in labeling which decreased the number of allowable claims and intensified the warnings about possible hazards. F.D.A. Commissioner,
Charles C. Edwards, criticized the drug industry for not helping to prevent the abuse of amphetamines. Thomas M. Rauch, president of SmithKline & French laboratories, responded that his company had long promoted stricter drug abuse legislation and tighter controls
on production and distribution. SmithKline & French also made Dexedrine and Benzedrine. The F.D.A. began to restrict amphetamine manufacturer claims to only three medical uses, two of them uncommon. The two rare conditions specified were narcolepsy
and hyperactivity. The third permitted use was for suppressing appetite among persons who needed to lose weight. However, this would only be allowed for a total of a few weeks, and as a part of
treatment for obesity.